摘要
目的研究rhIL-11(重组人白细胞介素-11)和rhTPO(重组人促血小板生成素)用于治疗化疗所致血小板减少症上的效果以及用药安全性。方法在该院肿瘤内科于2013年8月—2016年2月收治的化疗后出现血小板减少症患者中随机抽取出125例作为观察对象,按照治疗方法将其分成观察组(n=65)和对照组(n=60),其中观察组患者采用rhTPO治疗,对照组患者采用rhIL-11治疗,就两组患者的治疗效果、不良反应发生率等进行对比。结果观察组患者的治疗总有效率86.15%明显比对照组的71.67%高,且观察组患者不良反应发生率7.69%低于对照组的21.67%,P<0.05。另外观察组患者在血小板计数<50×109/L持续时间≥100×109/L耗费时间上,均短于对照组,P<0.05。结论在化疗所致的血小板减少症临床治疗中,重组人血小板生成素效果更好,能迅速提升患者的血小板计数,且用药安全性高,值得推广应用。
Objective To research the effects of rhIL-11(for chemotherapy in the treatment of recombinant human interleukin- 11) and rhTPO(recombinant human thrombopoietin) induced platelet reduce disease on the effect and safety of drug use. Methods From August 2013 to February 2016, 125 cases of patients with thrombocytopenia after chemotherapy in our hospital were selected as the observation object,according to the method of treatment will be divided into the observation group(n=65) and the control group(n=60), the observation group with rhTPO treatment, the control group were treated with rhIL-11 treatment, the therapeutic effect of two groups of patients, adverse reactions occurred rate were compared. Results The total effective rate of the observation group was 86.15% higher than that of the control group71.67%, and the incidence of adverse reactions in the observation group was 7.69% lower than that in the control group 21.67%,P < 0.05. Also observed group of patients in the platelet count < 50 ×109/L continuous time, is more than or equal to 100×109/L spend time were shorter than the control group, P < 0.05. Conclusion In chemotherapy induced platelet reduction in the treatment of disease, recombinant human thrombopoietin effect is better, can quickly improve the patient's platelet count, and drug safety, it is worth popularization and application.
出处
《系统医学》
2016年第12期121-123,共3页
Systems Medicine
作者简介
徐薇薇（1981.10-）,女,江苏南通人,本科,主治医师,研究方向：肿瘤内科学.
